PIPELINE

Our product and product candidate pipeline is summarized in the table below.

 

Product/
Product Candidate		 Indication Sought Status
INOMAX® (nitric oxide) for inhalation Hypoxic respiratory failure Marketed
Bronchopulmonary dysplasia Pivotal Phase III
IK-7001
inhaled nitric oxide
with INOpulse®		 Pulmonary arterial hypertension Phase II
Chronic obstructive pulmonary disease Phase III
LUCASSIN® (terlipressin) for injection Hepatorenal syndrome Type 1 Pivotal Phase III
Bioabsorbable Cardiac Matrix Cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction CE Registration Trial

 

Please see our Research & Development and Partners pages for information on the efforts driving our product growth.

 

Last updated January 2012

INOMAX and INOpulse are registered trademarks of INO Therapeutics LLC.

LUCASSIN is a registered trademark of Acorus Therapeutics Limited.